Ordering Recommendation

Order to diagnose factor VIII deficiency, detect factor VIII inhibitors, and monitor factor VIII replacement therapy.

Methodology

Electromagnetic Mechanical Clot Detection

Performed

Mon-Sat

Reported

1-3 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation
Collect

Lt. blue (sodium citrate). Refer to Specimen Handling at aruplab.com for hemostasis/thrombosis specimen handling guidelines.

Specimen Preparation

Transfer two 3 mL aliquots of platelet-poor plasma to ARUP Standard Transport Tubes. (Min: 2 mL/each)

Storage/Transport Temperature

CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.

Unacceptable Conditions

Serum. EDTA plasma, clotted or hemolyzed specimens.

Remarks
Stability

Ambient: 4 hours; Refrigerated: Unacceptable; Frozen at -20°C: 3 months; Frozen at -70°C: 6 months

Reference Interval

Test Number
Components
Reference Interval
  Bethesda Quantitative, F8 0.5 BU or less
  Factor VIII, Activity
Age
Reference Interval (%)
0-6 years 56-191
7-9 years 76-199
10-11 years 80-209
12-13 years 72-198
14-15 years 69-237
16-17 years 63-221
18 years and older 56-191

Interpretive Data



Compliance Category

Standard

Note

If Factor VIII activity is 20 percent or less, then Bethesda Quantitative, Factor VIII will be added.  Additional charges apply.

Hotline History

N/A

CPT Codes

85240; if reflexed, add 85335

Components

Component Test Code* Component Chart Name LOINC
0030028 Bethesda Quantitative, F8 3204-5
0030095 Factor VIII, Activity 3209-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Bethesda Quantitative Factor VIII, Inhibitor
  • Coagulation Factor VIII Inhibitor Panel, Plasma
  • Factor 8 Inhibitor
  • Factor VIII Inhibitor Profile
Factor VIII Activity with Reflex to Bethesda Quantitative, Factor VIII